Europe HIV Therapeutics Market Analysis

Europe HIV Therapeutics Market Analysis Summary

The Europe HIV therapeutics market is expected to reach $2.93 Bn by 2030, up from $2.61 Bn in 2022, with a CAGR of 1.44% from 2022 to 2030.

Human immunodeficiency virus (HIV) remains one of Europe's most serious communicable diseases. In 2020, 2.6 Mn people in the WHO European Region were HIV-positive. 77% of people living with HIV were aware of their HIV status. Antiretroviral therapy (ART) was used by 83 % of people with HIV who were diagnosed, and 95 % of those who received ART had viral suppression. Over the last decade, significant progress has been made in the WHO European Region toward UNAIDS's 2020 90-90-90 goals of 90% of people living with HIV knowing their HIV status, 90% of people with diagnosed HIV infection receiving sustained antiretroviral therapy (ART), and 90% of people receiving ART having viral suppression.

The WHO European Region is committed to achieving the global goal of eliminating AIDS as a public health threat by 2030, a commitment made when all 53 Member States endorsed the European Action Plan for the WHO European Region's health sector response to HIV. The European AIDS Clinical Society (EACS) develops guidelines for the care of HIV-positive people in Europe.

Market Dynamics

Market Growth Drivers Analysis

The RCC-THV is a European platform hosted by WHO/Europe for the interactive exchange of information and strengthened participation of national and international partners, including civil society organizations, in the prevention, diagnosis, treatment, and care of tuberculosis (TB), HIV, and viral hepatitis. The European Laboratory Initiative (ELI) was established by WHO/Europe. In 2018, the mission of ELI was expanded to include testing, diagnosis, monitoring, and laboratory needs for TB/HIV coinfection, HIV, and viral hepatitis, with the ultimate goal of strengthening and improving response to all three diseases in the WHO European Region. These factors may entice new entrants into Europe's HIV therapeutics market.

Market Restraints

However, progress toward these objectives varies across the region. According to the most recent data, the majority (80 % or nearly 85 000) of newly diagnosed people came from the eastern part of the Region, while countries in the European Union and European Economic Area (EU/EAA) saw a decrease in new diagnoses. A 24% decrease in the rate of newly diagnosed HIV cases between 2019 and 2020 is largely due to reduced HIV testing in 2020 as a result of COVID-19 restrictions and service disruptions. This is a concerning situation, given that new HIV infections have been on the rise in the WHO European Region over the last decade. Collectively, low access to treatment and care, fear of discrimination, and stigmatization.

Competitive Landscape

Key Players

• Bayer AG (DEU)
• Merck KGaA (DEU)
• Boehringer Ingelheim (DEU)
• BioNTech (DEU)
• Sanofi (FRA)
• AstraZeneca (GBR)
• Gilead Sciences France (FRA)
• British Biologicals (GBR)
• Merck & Co.
• AbbVie
• Bristol Myers Squibb

Recent Notable Updates

January 2023: Johnson & Johnson announced the termination of a late-stage global trial of the HIV vaccine after it was discovered to be ineffective at preventing infections. The failure of this trial comes more than a year after another of J&J's HIV vaccines failed a study, and it represents yet another setback in the search for a vaccine against a virus known to mutate quickly and find novel ways to evade the immune system.

March 2022: Moderna stated that by 2025, it would have developed and begun testing vaccines against 15 of the world's most dangerous pathogens. It would also have permanently waived the patents on its COVID-19 vaccine for use in low- and middle-income countries. Moderna unveiled its strategy ahead of the Global Pandemic Preparedness Summit. The UK government and the Coalition for Epidemic Preparedness Innovations (CEPI), a global alliance formed five years ago to anticipate potential future disease threats, both supported the summit. Among these collaborations are the International AIDS Vaccine Initiative and the HIV vaccine with the Gates Foundation.

Healthcare Regulations

The European Medicines Agency (EMA) regulates HIV therapeutics in Europe. The EMA is in charge of the scientific evaluation, supervision, and safety monitoring of medicines for human use in the European Union (EU). The European Medicines Agency (EMA) evaluates new HIV drugs and therapies for safety, efficacy, and quality before recommending to the European Commission whether they should be approved for marketing in the EU. The EMA also monitors the safety of these drugs after they are approved and has the authority to take regulatory action, such as revoking a drug's authorization, if there are safety concerns. This includes clinical trial design advice as well as regulatory requirements. In Europe, HIV therapeutics are regulated by national regulatory agencies in each member state, which are responsible for enforcing EU regulations in their respective countries. These agencies work closely with the EMA to ensure that HIV drugs are safe and effective for patients across the EU.

Reimbursement Policies

The reimbursement of HIV therapeutics in Europe varies by country, but most European Union (EU) and European Economic Area (EEA) countries have national health insurance schemes or other reimbursement programmes that cover the cost of HIV treatment. Access to HIV treatment and care is free or with a nominal co-pay in many EU countries, and is funded by a combination of government and private insurance funds. Some countries also have programmes to help people who are not covered by national health insurance schemes, such as undocumented migrants or asylum seekers, get ART and other HIV therapeutics.

In addition to national programmes, the EU funds HIV treatment and care through a variety of initiatives and organisations. The European AIDS Clinical Society (EACS), for example, provides clinical guidelines and recommendations for HIV management and works to promote HIV care integration into mainstream health services. Another organisation that supports HIV treatment and care in the region is the European Centre for Disease Prevention and Control (ECDC), which provides surveillance data, technical guidance, and other resources to aid in the prevention and management of HIV and other infectious diseases.